IBD 2007 – Achievements in Research and Clinical Practice

May 4–5, 2007
Hilton Convention Center
Istanbul

Program

Awarded with 12 CME credits
12 credit hours (CME) have been awarded for the Falk Symposium 159 by the European Union of Medical Specialists (UEMS) – European Board of Gastroenterology (EBG).
Preface

The recent observation about the increase in the incidence of Inflammatory Bowel Disease (IBD) and especially that of Crohn’s disease is not a myth. Much speculation has been done regarding the effect of some known and some unidentified risk factors which might account for this steady rise but one cannot deny the contribution of the faster and more effective spread of information between the scientists and the development of more sophisticated diagnostic techniques which enabled us to stratify the disease in a more comprehensive way.

Inflammatory bowel diseases come to the attention of the physician with different faces, different scenarios and even the same patient may show up with different patterns in various regions of the world.

When the clinical course seems not to be going so well despite appropriate medications, a search towards unexpected factors such as concomitant IBS, intercurrent infections and drug toxicity such as aminosalicylates should be considered. The impact of parasites, notably of amoeba or giardia, bacterial or viral infections deserve special attention in some parts of the world like the Eastern Mediterranean, North Africa, Middle East and Asia.

There is no single truth regarding the recognition and the management of IBD. In this regards the old dictum stating “there is no disease but the patient” should be the golden rule. Nowadays, the observation of more complicated Crohn’s disease cases at relatively young ages is not unusual. We come across with various clinical and extraintestinal manifestations we have hardly seen before. The evolution of the therapeutic armamentarium is now a double edged sword since “more drugs” may signify “more side effects, less compliance and more critical attitude of health authorities regarding reimbursement of the expenses”.

Education of the patient and the family, creation of empathy and a positive medium with the patient and a careful analysis of confounding/contributing factors to the disease behaviour are essential elements of an optimal therapy of IBD patients.

The Falk Symposium 159 on the “Achievements in Research and Clinical Practice in IBD” which will be held in Istanbul will be an excellent opportunity to discuss IBD and related issues in a less well known part of the world with respect to the prevalence, disease behaviour and patient’s characteristics as well as difficulties faced in the differential diagnosis and management.

As Paracelsus stated “The art of medicine cannot be inherited, nor can it be copied from books.” Nevertheless, it can be discussed in detail by the opinion leaders with worldwide reputation. From this standpoint there might be a conflict as to make a diagnosis of IBD with ample new techniques or to be more cost effective as Sir William Osler wisely expressed: “One finger in the throat and one in the rectum makes a good diagnostician.”

It is our great pleasure to host a Falk Symposium in Istanbul, a fairy city, a nice bridge between two continents, the seat of many civilizations, cultures, languages and religion. This sacred piece of land with its fine attractions, waiting to be explored, will certainly distract weary minds, fascinate the tired souls but also leave imprints in memory as knowledge, images and exotic sounds.

N. Tözün  Ü. Dağlı  G. Mantzaris  J. Schölmerich
IBD 2007 – Achievements in Research and Clinical Practice

Hilton Convention Center Istanbul

Registration:
Thursday, May 3, 2007
16.00–21.00 h
at the Congress Office

Scientific Organization:
Ü. Dağlı, Ankara (Turkey)
G. Mantzaris, Athens (Greece)
J. Schölmerich, Regensburg (Germany)
N. Tözün, Istanbul (Turkey)

Congress Venue:
Hilton Convention Center Istanbul
Cumhuriyet Caddesi
Harbiye 80200 Istanbul
Turkey

Information:
Prof. Dr. Nurdan Tözün
Marmara University
School of Medicine
Department of Gastroenterology
Tophanelioğlu Cad. 13–15
34662 Üsküdar/Istanbul
Turkey
Telephone: +90 (216) 3267073
or 3271010 Ext: 136
Telefax: +90 (216) 3267073
E-mail: drnurdantozun@yahoo.com

Official language:
English
(simultaneous translation into Turkish will be provided)

Posters:
For details see page 11.
Friday, May 4, 2007

9.00 Welcome

Session I: Epidemiology, risk factors and genetics
Chair: R.W. Stockbrugger, Maastricht; E. Tsianos, Ionnina

9.10 IBD in Turkey
Ü. Dağlı, Ankara

9.30 IBD in Greece
I. Triantafillidis, Athens

9.50 IBD in Southern Europe
B. Vucelic, Zagreb

10.10 Comparison to North and Central Europe
E. Langholz, Hellerup

10.30 Coffee break with poster session

Session II: Bacterial and viral infections mimicking IBD
Chair: W. Jafri, Karachi; M. Farthing, Glasgow

11.00 Tuberculosis of the colon: A diagnostic challenge
D. Epstein, Cape Town

11.20 Parasitic disorders as a diagnostic challenge
C. Kalaycı, Istanbul

11.40 Bacterial and viral infections mimicking IBD
M. Törüner, Ankara

12.00 Viral hepatitis and HIV
E. A. Kouroumalis, Heraklion

State-of-the-Art Lecture I
Chair: C. Arvanitakis, Thessaloniki

12.20 Differentiation of mechanism of action in biologics
L. Mayer, New York

12.50 Lunch break with poster session
Friday, May 4, 2007

Session III:
Diagnostic standards and developments in imaging

Chair: H. Herfarth, Chapel Hill; I. Rozanes, Istanbul

13.50 Conventional and novel endoscopy
14.10 Endoscopic and histologic grading
14.30 Conventional imaging
14.50 Novel imaging

15.10 Coffee break with poster session

Session IV:
Cases and controversies

Chair: D. Rachmilewitz, Jerusalem; N. Tözün, Istanbul

15.40 Case 1: Dominant pain in suspected CD
Moderator: D. P. Jewell, Oxford
Case presentation

16.00 Case 2: Dominant diarrhoea in suspected CD
Moderator: P. Rutgeerts, Leuven
Case presentation

16.20 Case 3: Refractory diarrhoea in UC
Moderator: M. Gassull, Badalona
Case presentation

State-of-the-Art Lecture II

Chair: D. Buğra, Istanbul

16.40 What is the role of surgery in IBD

17.10 End of afternoon session
Saturday, May 5, 2007

State-of-the-Art Lecture III
Chair: O. Manoussos, Athens

8.30 The changing face of IBD over the last decades  P. Rutgeerts, Leuven

Session V
Laboratory markers and other tools
Chair: S. Arslan, Ankara; S. Vermeire, Leuven

9.00 Antibodies: Useful tools or pathophysiology markers?  J.-F. Colombel, Lille
9.20 How to diagnose Behçet’s disease  A.F. Çelik, Istanbul
9.40 Molecular and biological markers for treatment decisions  S. Schreiber, Kiel
10.00 Stool tests: Are they useful?  I. Bjarnason, London
10.20 Coffee break with poster session

Session VI
Features of drugs used in IBD
Chair: A. Nakos, Athens; D.K. Podolsky, Boston

10.50 5-Aminosalicylic acid  U. Klotz, Stuttgart
11.10 Glucocorticosterioids  R. Löfberg, Stockholm
11.30 Azathioprine/6-MP, MTX and others  M.F. Neurath, Mainz
11.50 Antibiotics and probiotics  P. Gionchetti, Bologna
12.10 Alternative medications  A. Gangl, Vienna
Saturday, May 5, 2007

Session VII
Treatment algorithms: “The standard patient”
Chair: I.E. Koutroubakis, Heraklion; A. Tromm, Hattingen

12.30 Mild-to-moderate distal UC  
  G. Mantzaris, Athens

12.45 Mild-to-moderate extensive UC  
  P. Marteau, Paris

13.00 Mild-to-moderate ileocecal CD  
  V. Gross, Amberg

13.15 Mild-to-moderate colonic CD  
  H. A. Akbaylar, Izmir

13.30 Lunch break with poster session

State-of-the-Art Lecture IV
Chair: S. Boyacıoğlu, Ankara

14.30 Future therapies in IBD  
  J. Schölmerich, Regensburg
Saturday, May 5, 2007

Session VIII
Cases and Controversies
Chair: D. Karamanolis, Athens; C. Gasche, Vienna

15.00  CD with fistula
       Case presentation
       A. Roussos, Athens

15.20  The conservative approach
       H. Ö. Hamzaoğlu, Istanbul

15.40  The aggressive approach
       B. E. Sands, Boston

16.00  The surgical approach
       E. Geçim, Ankara

16.20  Conclusions
       M. Lémann, Paris

16.40  Coffee break with poster session

17.10  Refractory UC
       Case presentation
       N. Apostolou, Athens

17.30  The conservative approach
       H. S. Odes, Beer Sheva

17.50  The aggressive approach
       W. J. Sandborn, Rochester

18.10  The surgical approach
       S. Baratsis, Athens

18.30  Presentation of Poster Prizes
       J. Schölmerich, Regensburg

18.50  Concluding remarks
       N. Tözün, Istanbul

19.00  End of meeting
Poster Session

Posters will be exhibited on May 4–5, 2007, at the “Hilton Convention Center Hotel” Istanbul.

The authors will be in attendance during coffee and lunch breaks on both days.

Posters

1. Predictive factors of response and relapse to the azathioprine in patients with Crohn’s disease.
   S. Ajmi, A. Jmaa, A. Kahloun, L. Golli, M. Ksiaa, R. Jmaa, F. Derbel (Sousse, TN)

2. Association cyclosporine and azathioprine during the severe acute colitis: Does it avoid the colectomy?
   S. Ajmi, A. Jmaa, B. Fathallah, L. Golli, M. Ksiaa, R. Jmaa, F. Derbel (Sousse, TN)

3. Course of Crohn’s disease prior to establishment of the diagnosis – Results of the online-based “DMC-questioning”.

   T. Alempijevic, A. Pavlovic, S. Djuranovic, N. Kovacevic, R. Masnikosa, D. Tomic, M. Krstic (Belgrade, SCG)

5. The impact of “BioR” on evolution of ulcerative colitis.
   N.I. Antonova, S. Oprea, N. Bodrug (Chisinau, MOL)

6. The anemic syndrome in inflammatory bowel disease.
   D. Badea, M. Badea, A. Genunche-Dumitrescu (Craiova, RO)

7. Inflammatory bowel disease associated with essential thrombocythemia (case study).
   M. Badea, D. Badea, A. Genunche-Dumitrescu (Craiova, RO)

8. The thrombocytosis and inflammatory bowel disease.
   M. Badea, D. Badea, A. Genunche-Dumitrescu, C. Petrica (Craiova, RO)

   C. Banciu, O. Darie, L. Marian, I. Romosan (Timisoara, RO)
10. Osteoporosis as an extraintestinal manifestation in IBD patients.
C. Banciu, L.M. Susan, L. Marian, M. Savulea, I. Romosan (Timisoara, RO)

11. Evolution of epidemiological indices and clinical manifestation in ulcerative colitis in Moldova.
S. Barca, V.-T. Dumbrava, T. Tibuleac, S. Turcan (Chisinau, MOL)

M. Barreiro-de-Acosta, A. Lorenzo-González, J.E. Domínguez-Muñoz
(Santiago de Compostela, E)

L. Baticic, D. Detel, N. Varljen, B. Mijandrusic Sincic, J. Varljen (Rijeka, HR)

O.K. Bonderup, J.B. Hansen (Randers, Aalborg, DK)

K. Bulut, C. Pennartz, J.J. Meier, P. Felderbauer, M. Banasch, D. Bulut,
F. Schmitz, W.E. Schmidt, P. Hoffmann (Bochum, Essen, D)

16. Frequency of adenomatous polyps and dysplasia in inflammatory bowel disease.

M. Cakir, C. Arikan, M. Baran, H.A. Yuksekkaya, G. Tumgor, F. Ozgenc,
R.V. Yagci, S. Aydogdu (Izmir, TR)

18. Tuberculosis infection in patients with inflammatory bowel disease.
G. Can, H. Akin, H.Ö. Hamzaoglu, N. Tözün (Istanbul, TR)


H. Cetinkaya, M. Bektas, A. Tüzün, A. Ensari, E. Kahramanoglu, B. Savas,
M. Törüner (Ankara, TR)
M. Ciris, M. Isler, C. Savas, S. Bircan, M. Keskin (Isparta, TR)

22. The effect of caffeic acid phenethyl ester (CAPE) on TNBS-induced colitis.
M. Ciris, M. Isler, H. Cam, A. Koyu, N. Karahan (Isparta, TR)

23. The utility of serum MMP-3 in degree of activity in inflammatory bowel diseases.
S. Coban, N. Örmeci, O.F. Yolcu, I. Ertugrul, F. Ekiz, S. Ertek,
M. Palabiyikoglu, A. Ülker (Ankara, TR)

S. Cukovic-Cavka, N. Bozina, M. Brinar, K. Grubelic-Ravic, Z. Krznaric,
M. Rojnic Kuzman, N. Rustemovic, T. Brkic, R. Pulanic, J. Sertic, B. Vucelic
(Zagreb, HR)

25. Malignant transformation in ulcerative colitis – Experiences in a Hungarian clinical center.
Z. Czeglédi, T. Szamosi, K. Rabai, J. Banai (Budapest, H)

26. Steroid use is not the only cause of osteoporosis in inflammatory bowel disease.
R. D’Souza, N. Vansomerun, K. Besherdas, C. Somesundrum, H. Henoch
(Enfield, GB)

M. Dadalski, J. Kierkus, P. Socha, M. Szczepanski, J. Ryzko (Warsaw, PL)

28. Rectorrhagia and inflammatory bowel diseases.
D. Damian, A. Berecz, M. Grigorescu, M. Hogea, M. Rusu, M. Singeorzanz,
D. Stanciu (Cluj-Napoca, RO)

29. Predictive factors of chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis.
(Sousse, TN)

30. Predictive factors of glucocorticosteroid treatment failure in severe acute idiopathic colitis.
R.B.H. Hamida (Sousse, TN)
31. Effect of glutamine enriched total parenteral nutrition on inflammatory bowel disease.  
K. Derc, G. Skarupa-Szablowska, D. Mankowska, J. Przyslawski, K. Linke, M. Grzymislawski (Poznan, PL)

32. The glycosylation patterns of selected acute phase proteins in ulcerative colitis.  
K. Derc, G. Skarupa-Szablowska, M. Grzymislawski, M. Sobieska, K. Wiktorowicz (Poznan, PL)

33. Comparison of 5-ASA treatment modalities for the maintenance of remission in left-sided ulcerative colitis: A long-term follow-up study.  
S. Disibeyaz, M. Arhan, A.S. Koksal, E. Parlak, A. Ulker (Ankara, TR)

34. Retrospective evaluation of results of 1051 colonoscopy patients.  
U.M. Dogan, B. Abayli, G. Özgür (Adana, TR)

35. Outcomes of gravidity in 44 IBD patients – A single center experience.  
R. Donoval, A. Parizek, M. Bortlik, A. Novotny, V. Komarek, M. Lukas (Prague, CZ)

R. Donoval, O. Slanar, D. Duricová, M. Lukas (Prague, CZ)

37. Clinical and pathogenic peculiarities of indeterminate colitis.  
A.E. Dorofeyev (Donetsk, UKR)

38. Changes in extent of ulcerative colitis in relation to maintenance remission therapy.  

39. Is re-administration of infliximab (Remicade®) after previous failure in severe Morbus Crohn effective?  
N. Eleftheriadis (Ptolemaida, GR)

40. Could thrombocyte indices be used as disease activity markers in inflammatory bowel diseases?  

41. Relationship between serum neopterin levels and inflammatory bowel diseases activity.  
42. SP and CGRP differentially modulate epithelial cell restitution via expression of TGF-beta, TGF-alpha and EGF-receptor RNA in fibroblasts and mast cells in an in vitro wound assay.
    P. Felderbauer, K. Bulut, K. Hoeck, S. Deters, W.E. Schmidt, P. Hoffmann (Bochum, Essen, D)

43. Colectomy rates after infliximab for refractory ulcerative colitis and predictive factors.

44. The ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype, response to medical therapy or need for surgery in Hungarian patients with inflammatory bowel diseases.
    P. Fuszek, S. Fischer, P.L. Lakatos, L. Lakatos, A. Kovacs, T. Molnar, I. Altorjay, M. Papp, A. Szilvasi, J. Papp, P. Demeter, G.T. Toth, A. Tordai, H. Andikovics (Hungarian IBD Study Group, Budapest, Veszprem, Szeged, Debrecen, H)

45. Quality of life in Crohn’s disease.
    L. Gabalec (Usti nad Orlici, CZ)

    M. Gazouli, V. Atzaves, G.I. Mantzaris, A. Archimandritis, N.P. Anagnou (Athens, GR)

47. The serum level of TNF-alpha and the incidence of antineutrophil cytoplasmic antibodies (ANCA) in patients with inflammatory bowel disease.
    A. Genunche-Dumitrescu, D. Badea, M. Badea, P. Mitrut, C. Vere (Craiova, RO)

48. The long-term therapy in maintenance of remission in moderate ulcerative colitis.
    A. Genunche-Dumitrescu, D. Badea, P. Mitrut, M. Badea (Craiova, RO)

49. From a herbal medicine to a safe alternative therapy in inflammatory bowel disease.
    H. Gerhardt, F. Seifert (Mannheim, D)

50. The impact of a 24-hour telephone helpline on the management of patients with inflammatory bowel disease (IBD).
    S. Gethins, T. Duckett, J. Mayberry, J.S. De Caestecker, R.J. Robinson (Leicester, GB)
51. The impact of a nurse led telephone clinic on quality of inflammatory bowel disease.
   S. Gethins, J.S. De Caestecker, J.A.D. Stewart, R.J. Robinson (Leicester, GB)

52. Endoscopical aspects in the first diagnosis of Crohn’s disease.
   A. Goldis, R. Goldis, A. Rosianu, V. Lungu (Timisoara, RO)

53. Inflammatory bowel disease in Romania: Epidemiological aspects.
   A. Goldis, O. Pascu, C. Gheorghe (Timisoara, Bucharest, RO)

54. Extraintestinal manifestations in ulcerative colitis patients.
   L.S. Gotia, S.R. Gotia, L.M. Susan, C. Fira-Mladinescu (Timisoara, RO)

55. Modulation if innate defence in Crohn’s disease patients.
   S.R. Gotia, L.S. Gotia, L.M. Susan, C. Borza (Timisoara, RO)

56. Treatment of “three week sulphasalazine syndrome” with corticosteroids.
   F. Gündüz, T. Özer, A.E. Kedrah, V. Korten, H.Ö. Hamzaoglu (Istanbul, TR)

57. Refractory infantile Crohn’s disease (CD) partially responsive to infliximab.
   F. Gürakan, N. Uslu, Y. Usta, H. Demir, I.N. Saltik-Temizel, H. Özen,
   A. Yüce (Ankara, TR)

58. Preliminary study on bacterial translocation in serum of patients with inflammatory bowel disease.
   A. Gutiérrez, R. Francés, J. Such, M. N’Dongo, M. Garmendia, R. Jover,
   M. Pérez-Mateo (Alicante, E)

59. Evaluation of Fas/FasL expression in inflammatory bowel diseases.
   K. Guzinska-Ustymowicz, J. Czyzewska, J. Sieczka, A. Pyczynicz,
   A. Kemona, A. Chetnik, M. Niksa (Bialystok, PL)

60. Clinical significance of systolic abdominal murmur in patients with inflammatory bowel disease.
   C. Gyulai, T. Molnar, F. Nagy (Szeged, H)

61. The neutrophil respiratory burst is generally preserved in Crohn’s disease, but diminished by cigarette smoking.
   M. Harbord, D. Marks, S. Bloom (London, GB)

62. Src kinase is a key molecule in cell contact-mediated survival signaling in primary human colonic epithelial cells.
   C. Hoffmann, W. Falk, J. Schölmerich, G. Rogler, F. Obermeier
   (Regensburg, D; Zürich, CH)
63. Colon cancer and IBD: A different case report.
   I.G. Kalliakmanis, Ch. Kouvidou, P. Sfikas, P. Karantanos, N. Adraskelas,
   V. Artikis, E. Karkantzos (Athens, GR)

64. Anti-inflammatory potential of melanocortin peptides in intestinal inflam-
   mation.
   K. Kannengiesser, C. Maaser, A. Lügering, T. Brzoska, T.A. Luger,
   W. Domschke, T. Kucharzik (Münster, D)

65. The incidence of amebiasis in our patients with ulcerative colitis.
   B. Kantarceken, A. Cetinkaya, C. Citirik, H. Ciralik (Kahramanmaras, TR)

66. Demographical, clinical, laboratory and endoscopic aspects of patients with
   ulcerative colitis in our region.
   B. Kantarceken, A. Cetinkaya, C. Citirik, H. Ciralik (Kahramanmaras, TR)

67. Measurement of intestinal permeability used a lactulose/mannitol test
   depending on somatometric data.

68. Prospective registration and validation of possible risk factors of relapse in
   patients with inflammatory bowel disease (IBD).
   (Heraklion, GR)

69. Multidrug resistance (MDR) gene polymorphisms influence outcome of
   azathioprine and glucocorticoids in patients with inflammatory bowel
   disease.
   K. Katsanos, M. Ferrante, L. Henckaerts, D. Christodoulou, G. Van Assche,
   E.V. Tsianos, S. Vermeire, P. Rutgeerts (Ioannina, GR; Leuven, B)

70. Long-term safety of azathioprine treatment in inflammatory bowel disease:
   Results from a single referral center.
   K. Katsanos, M. Ferrante, H. Fidder, L. Henckaerts, D. Christodoulou,
   G. Van Assche, E.V. Tsianos, S. Vermeire, P. Rutgeerts (Ioannina, GR;
   Leuven, B)

71. Crohn’s disease presenting as multiple veins thrombosis.
   A.E. Kedrah, Y. Alahdab, F. Gündüz, C. Pata, Ö. Atug, N. Tözün
   (Istanbul, TR)

72. Polyneuropathy and autonomic neuropathy due to high dose 5-ASA.
   A.E. Kedrah, O. Atug, F. Gündüz, Y. Alahdab, N. Imeryuz, N. Tözün
   (Istanbul, TR)
73. NOD2/CARD15 gene mutations in Polish children with IBD – Frequency, distribution and relation to clinical presentation. 
J. Kierkus, P. Socha, H. Schmidt, M. Szczepanski, M. Dadalski, C. Büning, J. Ryzko (Warsaw, PL; Münster, Berlin, D)

74. Salmonella sepsis and HIV infection. 
R. Komitova, P. Petrov, M. Spasova, M. Radeva (Sofia, BG)

75. Early beneficial results of a synbiotic formula (Synbiotic 2000Forte) in Crohn’s disease patients. 
K. Kotzampassi (Thessaloniki, GR)

76. Nutritional status and nutritional characteristics of inflammatory bowel disease patients suffering from coincident hepatobiliary disorders. 
Z. Lelovics, K. Fekete, I. Henter, A. Molnár, L. Tátrai (Kaposvar, Budapest, H)

77. New method of determination of bile acid malabsorption in Crohn’s disease. 
M. Lenicek, J. Zelenka, M. Bortlik, M. Lukas, L. Vítek (Prague, CZ)

78. Changes of the expression of the Na\textsuperscript{+}/H\textsuperscript{+} exchanger NHE3 and the PDZ-adapter proteins PDZK1 and NHERF1 during inflammation in the colon of the interleukin-10-deficient mouse. 
H. Lenzen, A. Bleich, U. Seidler, M.P. Manns (Hannover, D)

79. Galectin-3 inhibits DSS-induced colitis in mice. 
Lippert, M. Gunckel, W. Falk, F. Obermeier, N. Dunger, G. Rogler (Regensburg, D; Zürich, CH)

80. Potential role of Mycobacterium avium subspecies paratuberculosis (MAP) in the etiopathogenesis of Crohn’s disease: A case-control study on intestinal tissue. 
A. Lozano-Leon, M. Barreiro-de-Acosta, B. Vieties, J. Forteza, A. Lorenzo-González, J.E. Dominguez-Muñoz (Santiago de Compostela, E)

K. Malickova, M. Lukas, R. Donoval, P. Sandova, I. Janatkova (Prague, CZ)

82. Extraintestinal manifestations and complications at patients with inflammatory bowel diseases. 
I. Marincu, M. Cornianu, C. Oancea, L. Marincu (Timisoara, RO)
83. Analysis of predicting factors of leukocytapheresis to patients with intractable moderate to severe ulcerative colitis – A multicenter prospective open label study.
   T. Matsumoto, K. Fukunaga, A. Andoh, K. Okawa, H. Ito, A. Torii, S. Yoshikawa, R. Nakaoka, Y. Okuyama, K. Watanabe, M. Nishishita, Y. Fujiyama (Kinki IBD Study Group, Nishinomiya, Otsu, Osaka, Kyoto, Yamatotakada, Osakasayama, J)

84. NOD1 gene E266K (G796A) polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn’s disease.

85. Strictureing esophageal disease complicating glycogen storage disease type 1b (GSB-1b): Case report.
   P. Nicolaou, P. Petrikos, G. Bamias, K. Makrilakis, C. Mavrogiannis, N. Katsilambros, I. Vafiadi (Athens, GR)

86. The value of serum TGF-beta1 in degree of activity in inflammatory bowel diseases.
   N. Örmeci, Ö.F. Yolcu, S. Coban, I. Ertugrul, F. Ekiz, S. Ertek, M. Palabiyikoglu, A. Ülker (Ankara, TR)

87. Diagnostic value of procalcitonin in determining the activity of IBD.
   N. Oruc, O. Ozutemiz, N. Osmanoglu, T. İlter (İzmir, TR)

88. Thrombosis in ulcerative colitis.
   N. Osmanoglu (İzmir, TR)

89. Safety of infliximab treatment in Crohn’s disease.
   H. Over-Hamzaoglu, R. Farrell, Y. Gittin, J. Goldstein, M.A. Peppercorn (İstanbul, TR; Boston, USA)

90. The coexistancy of microscopic colitis and focal active colitis in patients with irritable bowel syndrome.

91. Gene polymorphisms in Turkish patients with inflammatory bowel disease.
92. Health-related quality of life (HRQOL) in patients with inflammatory bowel disease.
    D. Panova, Z. Krastev (Sofia, BG)

93. Favorable response to subcutaneous administration of growth factors in experimental colitis in rats.

94. Minor findings in patients subjected to capsule endoscopy for the evaluation of suspected Crohn’s disease. Implications in our therapeutic decision.
    K. Papaxoinis, N. Viazis, I. Theodoropoulos, D. Georgiadis, D.G. Karamanolis (Athens, GR)

95. Azathioprine/6-mercaptopurine (AZA/6-MP) reduces the risk of intestinal re-operation in Crohn’s disease (CD).
    P. Papay, E. Ho, W. Reinisch, W. Miehsler, H. Vogelsang, G. Novacek (Vienna, A)

96. Laparoscopic restorative proctocolectomy for colitis ulcerosa.
    A. Papp, K. Morvay, C. Fülöp, H. Horváth, P. Kupcsulik (Budapest, H)

97. Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.
    K. Patsiaoura, P. Zezos, N. Nikolaidis, T. Vassiliadis, O. Giouleme, A. Mpoumponaris, N. Evgenidis (Thessaloniki, GR)

    O. Petrascu, A.B. Boicean, M. Deac, R. Mihaila (Sibiu, RO)

99. Is endoscopy really helpful in the diagnosis of IBD in children?
    S. Pieczarkowski, P. Kwinta, A. Wedrychowicz, M. Sladek, K. Fyderek, A. Opoka, A. Miska (Cracow, PL)

100. Restorative proctocolectomy as recue therapy for pediatric patients with ulcerative colitis.
    S. Pieczarkowski, E. Grochowska, M. Krysta, M. Sladek, A. Wedrychowicz, K. Fyderek (Cracow, PL)

101. Inflammatory bowel disease and scores at the SF36 quality of life questionnaire.
    C. Pojoga, D.L. Dumitrascu (Cluj-Napoca, RO)
102. Terminal ileitis in children with IBD.
A.S. Potapov, E.G. Tsimbalova, P.L. Shcherbakov, M.M. Lochmatov,
E.S. Dublina (Moscow, R)

103. Relationship between bone mineral density and clinical features in patients
with inflammatory bowel disease: A local study in Turkish population.
S. Poturoglu, F. Balkan, Z. Ermis Karaali, S. Budak, S. Yanmaz, T. Alioglu,
M. Kendir (Istanbul, TR)

104. CD1c+ and CD303+ dendritic cells in patients with ulcerative colitis and
Crohn’s disease.
K. Radwan-Kwiatek, P. Radwan, J. Tabarkiewicz, J. Roliski (Lublin, PL)

105. Practicality and feasibility of CT enterography (CT-E) in patients with Crohn’s
disease: A community hospital experience.
M. Ramani, P. Godet, D.A. Valenti, L.A. Stein (Montreal, CDN)

106. Differential effects of anti-TNF antibodies on activated macrophages and
dendritic cells in vivo and in vitro.
M. Ross, S. Koch, P. Lebiedz, W. Domschke, A. Lügering, T. Kucharzik
(Münster, D)

107. Dual role of endogenous nitric oxide in development of dextran sodium
sulfate-induced colitis in rats.
(Pecs, H; Kyoto, J)

108. Antiviral treatment in Crohn’s patients with chronic hepatitis C is well
tolerated and effective.
T.M. Scherzer, K. Stauffer, C. Gurguta, G. Novacek, P. Ferenci, H. Vogelsang
(Vienna, A)

109. Long-term outcome of treatment with infliximab in 440 Crohn’s disease
patients: Results from a single center cohort.
F. Schnitzler, H. Fidder, M. Ferrante, M. Noman, G. Van Assche, I. Hoffman,
S. Vermeire, P. Rutgeerts (Leuven, B)

110. The mRNA expression levels for the NHE3 adapter protein PDZK1 (NHERF3)
but not for the Na+/H+ exchanger NHE3 are severely downregulated in the
colonic mucosa of patients with active IBD – Implications for the dysregula-
tion of salt and water transport.
K. Schröder, B. Riederer, O. Bachmann, K. Franke, H. Lenzen, J. Wedemeyer,
C. Meyer, M.P. Manns, U. Seidler (Hannover, D)
111. Effects of exopolysaccharide producing probiotic strains on mast cells in experimental colitis.

112. Hepatotoxicity induced by azathioprine in a patient with refractory ulcerative colitis.
P. Sfikas, I.G. Kalliakmanis, P. Karantanos, V. Arseniou, N. Adraskelas, E. Karkantzos (Athens, GR)

113. Efficacy of colesvelam in Crohn’s disease patients with diarrhea.
J.A. Shah, M. Musa, T. Valliani, R. Przemioslo (Bristol, GB)

114. The prevalence of microscopic colitis and celiac disease in the patients with irritable bowel syndrome.

M. Sladek, U. Jedynak-Wasowicz, A. Wedrychowicz, K. Kowalska-Duplaga, S. Pieczarkowski, K. Fyderek (Cracow, PL)

116. A clinical evolving study of ulcerative colitis over a 15 years period.
L.M. Susan, V.M. Ancusa, A. Pacurari, C. Dascau (Timisoara, RO)

117. Treatment of hemorrhagical rectocolitis with Salofalk® enemas and Salofalk® suppositoria.
E. Tcaciuc, S. Matcovschi, A. Tcaciuc (Chisinau, MOL)

118. Evaluation of association of NOD2/CARD15 genotypes with clinical course of Turkish Crohn’s disease patients.
F. Tekin, A. Berdeli, A. Aydin, O. Ozutemiz, A. Musoglu, N. Osmanoglu, T. Ilter (Izmir, TR)

119. Evaluation of 100 Crohn’s disease patients according to the Vienna and Montreal classifications.
F. Tekin, T. Ilter, N. Osmanoglu (Izmir, TR)

120. Granulomatous cheilitis in a patient with Crohn’s disease: A pictorial follow-up description.
J.K. Triantafillidis, F. Zervou, E. Merikas, P. Cheracakis, G. Peros (Athens, GR)

J.K. Triantafillidis, A. Stamataki, A. Gikas, A. Cheracakis, E. Papavassiliou, F. Georgopoulos, G. Malgarinos, J. Fouskas (Athens, GR)
122. Osteoporosis in children with IBD.
E.G. Tsimbalova, A.S. Potapov, O.V. Tchoumakova, E.S. Dublina (Moscow, R)

123. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
G. Tsiolakidou, I.E. Koutroubakis, A. Sfirimaki, K. Koukoutsi, A. Theodoropoulou, E.A. Kouroumalis (Heraklion, Heraklion, Crete, GR)

124. Ulcerative colitis and viral hepatitis.
S. Turcan, V.-T. Dumbrava, A. Sofroni, R. Tanase, S. Barca (Kishinev, MOL)

O. Tutina, E. Fedulova, V.N. Kopeikin, I. Mayanskaya, N. Tolkacheva (Nizhniy Novgorod, R)

126. Correlation between endoscopic severity and the histologic activity index in inflammatory bowel disease.

127. An alternative treatment option when conventional therapy fails in Behcet’s disease: Infliximab.
M. Ugras, D. Ertem, E. Pehlivanoglu (Istanbul, TR)

128. Analysis of ulcerative colitis patients in Ondokuz Mayis University: Report of 90 cases.
M. Ustaoglu, N. Selim, B. Cakar, T. Bakir, A. Bektas (Samsun, TR)

129. Evaluation of our Crohn’s disease patients with upper gastrointestinal tract involvement.
S. Uysal, B. Tunc, Ü. Daglı, S. Kuran, A. Ülker (Ankara, TR)

130. Location of our ulcerative colitis patients according to Montreal classification: Is there any change by the years?

131. Evaluation of our operated ulcerative colitis patients.

133. The predictor parameters of relapse in ulcerative colitis.  
V. Vacariu, A. Pacurari, I. Romosan (Timisoara, RO)

134. Amebiasis in IBD: Silent passenger or disease modifier?  
E. Vardareli, A. Tiftikci, C. Baysal, N. Tözün (Istanbul, TR)

135. The predictive value of capsule endoscopy in the differential diagnosis of indeterminate colitis.  
N. Viazis, K. Papaxoinis, I. Theodoropoulos, E. Komninou, D. Karamanolis (Athens, GR)

136. Balloon dilatation in patients with Crohn’s disease.  
C. Viellieber, H. Schwacha, H.E. Blum (Freiburg, D)


D. Wasko-Czopnik, L. Paradowski (Wroclaw, PL)

139. Fertility, pregnancy, nursing and sexual health in inflammatory bowel disease.  

140. The effect of iNOS inhibitors treatment in experimental colitis models.  

141. Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis.  
P. Zezos, G. Papaioannou, N. Nikolaidis, K. Patsiaoura, T. Vassiliadis, O. Giouleme, A. Mpoumponaris, N. Evgenidis (Thessaloniki, GR)

142. Anti-Saccharomyces cerevisiae antibodies (ASCAs) in celiac disease.  
E. Zöld, Z. Barta, I. Csipő, M. Zeher (Debrecen, H)
List of Speakers, Moderators and Scientific Organizers

Prof. Dr. Hale Akpınar Akbaylar
Dokuz Eylül University
Faculty of Medicine
Department of Gastroenterology
35340 Inciralti/Izmir
Turkey
Hale.akbaylar@deu.edu.tr

Dr. S. Baratsis
Evangelismos Hospital
Surgical Clinic A
45–47, Ipsilantou str.
10675 Athens
Greece
sotbar@otenet.gr

Dr. Hakan Akin
Marmara University
School of Medicine
Department of Gastroenterology
Tophanelioglu Cad. 13–15
34662 Üsküdar/İstanbul
Turkey
dr_hakan_akin@yahoo.com

Dr. I. Bjarnason
King’s College School of Medicine and Dentistry
Dept. of Clinical Biochemistry
Bessemer Road
London SE5 9PJ
Great Britain
ingvar.bjarnason@kcl.ac.uk

Prof. Dr. Filiz Akyüz
Istanbul University
Faculty of Medicine
Department of Gastroenterology
Milllet Caddesi, Capa
34390 Istanbul
Turkey

Prof. Dr. Sedat Boyacıoğlu
MESA Hospital
Gastroentrology Division
Yasam Caddesi No. 5
06510 Söğütözü/Ankara
Turkey
boyacioglu@yahoo.com

Prof. Dr. Nickolaos Apostolou
Evangelismos Hospital
Gastroenterology Clinic A
45–47, Ipsilantou str.
10675 Athen
Greece
nikoshoika@yahoo.com

Prof. Dr. Dursun Buğra
Istanbul University
Faculty of Medicine
Department of General Surgery
Milllet Caddesi
34390 Çapa/Istanbul
Turkey
dbugra@doruk.net.tr

Prof. Dr. Serap Arslan
Hacettepe University
Faculty of Medicine
Department of Gastroenterology
06100 Sihhiye/Ankara
Turkey
searslan@hacettepe.edu.tr

Assoc. Prof. Dr. Aykut Ferhat Çelik
Istanbul University
Cerrahpaşa Faculty of Medicine
Department of Gastroenterology
34098 Cerrahpaşa/Istanbul
Turkey
afcelik@superonline.com

Prof. Dr. Constantine Arvanitakis
P.O. Box 60322
57001 Thermi/Thessaloniki
Greece
carvanit@med.auth.gr
Prof. Dr. Markus F. Neurath
Innere Medizin I
Klinikum der Universität
Langenbeckstr. 1
55131 Mainz
Germany
neurath@1-med.klinik.uni-mainz.de

Prof. Dr. H. Selwyn Odes
Ben Gurion Univ. of the Negev
Soroka Medical Center
Department of Gastroenterology
P.O. Box 151
84105 Beer Sheva
Israel
odes@bgumail.bgu.ac.il

Daniel K. Podolsky, M.D.
Professor of Medicine
Massachusetts General Hospital
School of Medicine
GI Unit
55 Fruit Street
Boston MA 02114-2696
USA
dpodolsky@partners.org

Prof. Dr. Daniel Rachmilewitz
Shaare Zedek Medical Center
Department of Medicine
P.O. Box 3235
91031 Jerusalem
Israel
tamid@netvision.net.il

Dr. Anastassios Roussos
Evangelismos Hospital
Gastroenterology Clinic A
45–47, Ipsilantou str.
10675 Athen
Greece
aroussos1971@yahoo.gr

Prof. Dr. Izzet Rozanes
Istanbul University
Faculty of Medicine
Department of Radiology
Milliet Caddesi, Capa
34390 Istanbul
Turkey
rozanes@superonline.com

Prof. Dr. Paul Rutgeerts
Univ. Ziekenhuis Gasthuisberg
Department of Gastroenterology
Herestraat 49
3000 Leuven
Belgium
paul.rutgeerts@uz.kuleuven.ac.be

William J. Sandborn, M.D.
Professor of Medicine
Mayo Clinic
Division of Gastroenterology
West 19A
200 First Street SW
Rochester MN 55905
USA
sandborn.william@mayo.edu

Bruce E. Sands, M.D.
Massachusetts General Hospital
School of Medicine
55 Fruit Street
Boston MA 02114-2696
USA
bsands@partners.org

Prof. Dr. Jürgen Schölmerich
Klinik für Innere Medizin I
Klinikum der Universität Regensburg
93042 Regensburg
Germany
juergen.schoelmerich@klinik.uni-regensburg.de
Congress Office

During the Falk Symposium 159
Hilton Convention Center
Istanbul
Cumhuriyet Caddesi
Harbiye 80200 Istanbul
Turkey

Telephone: +90 (212) 3156198
Telefax: +90 (212) 3156199

Opening Hours:
Thursday, May 3, 2007 16.00–21.00 h
Friday, May 4, 2007 8.00–17.10 h
Saturday, May 5, 2007 8.00–19.00 h

Congress Fees

Scientific program of the Falk Symposium 159 € 200.–
Students and residents € 100.–

*** OR***

Day ticket € 120.–
For students and residents € 60.–

The congress fees include:
– Welcome Evening on May 3, 2007
– Refreshments during coffee breaks
– Lunch on May 4 and 5, 2007
– A copy of the symposium’s abstract volume

Admission to Scientific Events
For admission to scientific events your name badge should be clearly visible.

Congress Report
The official congress report of the Falk Symposium 159 “IBD 2007 – Achievements in Research and Clinical Practice” will be published in English in the second half of 2007 by Springer, Dordrecht, Netherlands. Orders for this book at a reduced subscription price of € 35.– can be placed at the Congress Office during the congress in Istanbul.
Congress Short Report
The congress short report of the Falk Symposium 159 “IBD 2007 – Achievements in Research and Clinical Practice” will be published by the Falk Foundation e.V. with number FSK 159 in the second half of 2007. Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.

Airport
International Airport Istanbul
We help
by providing innovative medicines for bowel and liver diseases.

We promote knowledge
from 1967 onwards, there have been more than 200 international Falk Symposia and Workshops with over 100,000 participants from more than 100 countries

1 million doctors and patients have attended over 11,000 Falk educational meetings during the last 30 years

our Literature and Patient Information Service – including on-line ordering through our website.
General Information:

Falk Foundation e.V.
Congress Division
Leinenweberstr. 5
P.O. Box 6529
79041 Freiburg/Br.
Telephone: ++49 (761) 1514-0
Telefax: ++49 (761) 1514-359
E-mail: symposia@falkfoundation.de

www.falkfoundation.de